{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:39:41Z","timestamp":1783730381571,"version":"3.55.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:00:00Z","timestamp":1656028800000},"content-version":"am","delay-in-days":358,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","award":["HHSN268201700002I"],"award-info":[{"award-number":["HHSN268201700002I"]}],"id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","award":["HHSN268201700001I"],"award-info":[{"award-number":["HHSN268201700001I"]}],"id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","award":["HHSN268201700003I"],"award-info":[{"award-number":["HHSN268201700003I"]}],"id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","award":["HHSN268201700004I"],"award-info":[{"award-number":["HHSN268201700004I"]}],"id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","award":["HHSN268201700005I"],"award-info":[{"award-number":["HHSN268201700005I"]}],"id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HHSN268201700005I"],"award-info":[{"award-number":["HHSN268201700005I"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5T32HL007180-44"],"award-info":[{"award-number":["5T32HL007180-44"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.dld.2021.02.005","type":"journal-article","created":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T09:33:13Z","timestamp":1614159193000},"page":"873-878","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Association between the soluble receptor for advanced glycation end products (sRAGE) and NAFLD in participants in the Atherosclerosis Risk in Communities Study"],"prefix":"10.1016","volume":"53","author":[{"given":"Marci","family":"Laudenslager","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Lazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Selvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Hung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S.","family":"Pankow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne M.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.dld.2021.02.005_sbref0001","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.dld.2021.02.005_sbref0002","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.dld.2021.02.005_sbref0003","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease - A global public health perspective","volume":"70","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"issue":"21","key":"10.1016\/j.dld.2021.02.005_sbref0004","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMra1503519","article-title":"Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis","volume":"377","author":"Diehl","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.dld.2021.02.005_sbref0005","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1053\/j.gastro.2010.09.038","article-title":"Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study","volume":"140","author":"Williams","year":"2011","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.dld.2021.02.005_sbref0006","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","article-title":"Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States","volume":"148","author":"Wong","year":"2015","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.dld.2021.02.005_sbref0007","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1053\/bega.2002.0333","article-title":"Pathogenesis of steatohepatitis","volume":"16","author":"Day","year":"2002","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.dld.2021.02.005_sbref0008","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/2151302","article-title":"RAGE is a potential cause of onset and progression of nonalcoholic fatty liver disease","volume":"2019","author":"Asadipooya","year":"2019","journal-title":"Int J Endocrinol"},{"issue":"35","key":"10.1016\/j.dld.2021.02.005_sbref0009","doi-asserted-by":"crossref","first-page":"8026","DOI":"10.3748\/wjg.v22.i35.8026","article-title":"Dietary advanced glycation end-products aggravate non-alcoholic fatty liver disease","volume":"22","author":"Leung","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10.1016\/j.dld.2021.02.005_sbref0010","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jhep.2013.11.033","article-title":"Dietary glycotoxins exacerbate progression of experimental fatty liver disease","volume":"60","author":"Leung","year":"2014","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.dld.2021.02.005_sbref0011","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/ncpendmet0786","article-title":"Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications","volume":"4","author":"Yan","year":"2008","journal-title":"Nat Clin Pract Endocrinol Metabol"},{"issue":"5","key":"10.1016\/j.dld.2021.02.005_sbref0012","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1053\/jhep.2001.28788","article-title":"Up-regulated expression of the receptor for advanced glycation end products in cultured rat hepatic stellate cells during transdifferentiation to myofibroblasts","volume":"34","author":"Fehrenbach","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.02.005_sbref0013","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40001-015-0090-z","article-title":"Role of receptor for advanced glycation end products (RAGE) in liver disease","volume":"20","author":"Yamagishi","year":"2015","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.dld.2021.02.005_sbref0014","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1146\/annurev-med-041316-085215","article-title":"Targeting RAGE signaling in inflammatory disease","volume":"69","author":"Hudson","year":"2018","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.dld.2021.02.005_sbref0015","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.biocel.2014.10.001","article-title":"The receptor for advanced glycation end products influences the expression of its S100 protein ligands in melanoma tumors","volume":"57","author":"Meghnani","year":"2014","journal-title":"Int J Biochem Cell Biol"},{"issue":"4","key":"10.1016\/j.dld.2021.02.005_sbref0016","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/hep.26491","article-title":"Advanced glycation endproducts induce fibrogenic activity in nonalcoholic steatohepatitis by modulating TNF-alpha-converting enzyme activity in mice","volume":"58","author":"Jiang","year":"2013","journal-title":"Hepatology"},{"issue":"51","key":"10.1016\/j.dld.2021.02.005_sbref0017","doi-asserted-by":"crossref","first-page":"35507","DOI":"10.1074\/jbc.M806948200","article-title":"Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases","volume":"283","author":"Zhang","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.dld.2021.02.005_sbref0018","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.mce.2018.08.010","article-title":"Crosstalk between advanced glycation end products and vitamin D: a compelling paradigm for the treatment of ovarian dysfunction in PCOS","volume":"479","author":"Merhi","year":"2019","journal-title":"Mol Cell Endocrinol"},{"issue":"5","key":"10.1016\/j.dld.2021.02.005_bib0019","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1373\/clinchem.2016.264135","article-title":"Cross-sectional analysis of AGE-CML, sRAGE, and esRAGE with diabetes and cardiometabolic risk factors in a community-based cohort","volume":"63","author":"Loomis","year":"2017","journal-title":"Clin Chem"},{"key":"10.1016\/j.dld.2021.02.005_bib0020","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1475-2840-7-29","article-title":"The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes","volume":"7","author":"Meerwaldt","year":"2008","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"10.1016\/j.dld.2021.02.005_sbref0021","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/ki.2009.419","article-title":"Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease","volume":"77","author":"Basta","year":"2010","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.dld.2021.02.005_sbref0022","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/01.tp.0000280556.16275.2a","article-title":"Low levels of sRAGE are associated with increased risk for mortality in renal transplant recipients","volume":"84","author":"Gross","year":"2007","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.dld.2021.02.005_sbref0023","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.2337\/db12-1528","article-title":"sRAGE and risk of diabetes, cardiovascular disease, and death","volume":"62","author":"Selvin","year":"2013","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.dld.2021.02.005_sbref0024","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.2337\/db13-1636","article-title":"RAGE regulates the metabolic and inflammatory response to high-fat feeding in mice","volume":"63","author":"Song","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.dld.2021.02.005_sbref0025","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.metabol.2018.01.023","article-title":"Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify non-alcoholic fatty liver disease in age-, sex- and BMI-matched normo-glycemic adults","volume":"83","author":"Palma-Duran","year":"2018","journal-title":"Metab Clin Exp"},{"issue":"4","key":"10.1016\/j.dld.2021.02.005_sbref0026","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/oxfordjournals.aje.a115184","article-title":"The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives","volume":"129","year":"1989","journal-title":"Am J Epidemiol"},{"issue":"1\u20132","key":"10.1016\/j.dld.2021.02.005_sbref0027","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.clinbiochem.2013.11.005","article-title":"Three-year variability in plasma concentrations of the soluble receptor for advanced glycation end products (sRAGE)","volume":"47","author":"Bower","year":"2014","journal-title":"Clin Biochem"},{"issue":"8","key":"10.1016\/j.dld.2021.02.005_sbref0028","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/s41430-018-0346-0","article-title":"Coffee consumption and liver-related hospitalizations and deaths in the ARIC study","volume":"73","author":"Hu","year":"2019","journal-title":"Eur J Clin Nutr"},{"issue":"4","key":"10.1016\/j.dld.2021.02.005_sbref0029","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jhep.2014.11.024","article-title":"The association of liver enzymes with biomarkers of subclinical myocardial damage and structural heart disease","volume":"62","author":"Lazo","year":"2015","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.dld.2021.02.005_sbref0030","doi-asserted-by":"crossref","DOI":"10.3390\/jcm7080219","article-title":"Simple scores of fibrosis and mortality in patients with NAFLD: a systematic review with meta-analysis","volume":"7","author":"Salomone","year":"2018","journal-title":"J Clin Med"},{"issue":"5","key":"10.1016\/j.dld.2021.02.005_sbref0031","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.ahj.2015.08.008","article-title":"Soluble receptor for advanced glycation end products and the risk for incident heart failure: the atherosclerosis risk in communities study","volume":"170","author":"Lazo","year":"2015","journal-title":"Am Heart J"},{"issue":"22","key":"10.1016\/j.dld.2021.02.005_sbref0032","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1161\/01.CIR.0000039325.03698.36","article-title":"RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice","volume":"106","author":"Bucciarelli","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.dld.2021.02.005_sbref0033","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.2337\/db12-1528","article-title":"Comment on: Selvin et al. sRAGE and risk of diabetes, cardiovascular disease, and death","volume":"62","author":"Yamagishi","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.dld.2021.02.005_sbref0034","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.2741\/e178","article-title":"Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker","volume":"2","author":"Yamagishi","year":"2010","journal-title":"Front Biosci"},{"key":"10.1016\/j.dld.2021.02.005_bib0035","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.metabol.2017.04.003","article-title":"Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic\/histological parameters in various liver diseases","volume":"72","author":"Ballestri","year":"2017","journal-title":"Metab Clin Exp"},{"issue":"4","key":"10.1016\/j.dld.2021.02.005_bib0036","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.jhep.2013.05.044","article-title":"From NAFLD in clinical practice to answers from guidelines","volume":"59","author":"Nascimbeni","year":"2013","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.dld.2021.02.005_sbref0037","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1478-3231.2009.02192.x","article-title":"Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients","volume":"30","author":"Kim","year":"2010","journal-title":"Liver Int: Off J Int Assoc Study Liver"},{"issue":"10","key":"10.1016\/j.dld.2021.02.005_bib0038","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","article-title":"Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease","volume":"7","author":"Shah","year":"2009","journal-title":"Clin Gastroenterol Hepatol: Off Clin Pract J Am Gastroenterol Assoc"},{"issue":"6","key":"10.1016\/j.dld.2021.02.005_sbref0039","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.dld.2021.02.005_bib0040","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1053\/jhep.2003.50291","article-title":"Hepatitis C virus infection and incident type 2 diabetes","volume":"38","author":"Mehta","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.02.005_bib0041","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1155\/2019\/2151302","article-title":"RAGE is a potential cause of onset and progression of nonalcoholic fatty liver disease","volume":"2019","author":"Asadipooya","year":"2019","journal-title":"Int J Endocrinol"},{"issue":"2","key":"10.1016\/j.dld.2021.02.005_bib0042","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/cpt.148","article-title":"Emerging targets for therapeutic development in diabetes and its complications: the RAGE signaling pathway","volume":"98","author":"Litwinoff","year":"2015","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.dld.2021.02.005_sbref0043","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s12272-014-0527-x","article-title":"Deoxycholic acid-modified polyethylenimine based nanocarriers for RAGE siRNA therapy in acute myocardial infarction","volume":"38","author":"Ku","year":"2015","journal-title":"Arch. Pharm. Res."},{"issue":"6","key":"10.1016\/j.dld.2021.02.005_sbref0044","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.2337\/db16-1281","article-title":"RAGE-Aptamer blocks the development and progression of experimental diabetic nephropathy","volume":"66","author":"Matsui","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.dld.2021.02.005_bib0045","doi-asserted-by":"crossref","first-page":"22450","DOI":"10.1038\/srep22450","article-title":"Small molecule inhibition of ligand-stimulated RAGE-DIAPH1 signal transduction","volume":"6","author":"Manigrasso","year":"2016","journal-title":"Sci Rep"},{"issue":"17","key":"10.1016\/j.dld.2021.02.005_bib0046","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1212\/WNL.0000000000000364","article-title":"Clinical trial of an inhibitor of RAGE-Abeta interactions in Alzheimer disease","volume":"82","author":"Galasko","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.dld.2021.02.005_bib0047","unstructured":"Study of azeliragon in patients with mild Alzheimer's disease and impaired glucose tolerance. https:\/\/ClinicalTrials.gov\/show\/NCT03980730."}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865821000578?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865821000578?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:32:24Z","timestamp":1778823144000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865821000578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":47,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S1590865821000578"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2021.02.005","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between the soluble receptor for advanced glycation end products (sRAGE) and NAFLD in participants in the Atherosclerosis Risk in Communities Study","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2021.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}